Seaport Therapeutics and Hemab Therapeutics filed S-1 registration statements with the SEC between Wednesday evening and Thursday morning, hours after Kailera Therapeutics priced its IPO at $16.00 per share to raise $150 million. Three biotech offerings entering the public market pipeline within a 36-hour window represents the tightest clustering of life sciences IPO activity since May 2023, when four oncology-focused companies filed within five trading days.
Kailera's pricing came in at the midpoint of its expected $15.00-$17.00 range, a structurally significant detail. Midpoint pricing typically signals that the book was clean but not oversubscribed, and that underwriters saw no reason to artificially suppress the entry valuation. The company's lead indication targets rare metabolic disorders with defined patient populations under 8,000 cases annually in the United States. Seaport, meanwhile, is advancing a psychiatric disorder pipeline with Phase 2 data expected in Q3 2025. Hemab focuses on hemophilia B gene therapy with interim durability data readouts planned for late this year. Neither disclosed initial size targets in their preliminary filings.
The simultaneity matters because life sciences IPO windows close faster than they open. Biotechs with 12-to-18-month cash runways have been watching the XBI biotech ETF, which has traded sideways between $68 and $74 since October but has not broken below its 200-day moving average since early March. When one company prices successfully at midpoint and two others immediately file, it suggests that investment banks have been holding a backlog and saw Kailera's execution as the signal to release it. This is not enthusiasm. It is tactical queue management. The underwriters want to clear three deals before volatility returns or the Fed pivots hawkish again.
Allocators should note that all three companies are pre-revenue and will burn between $80 million and $120 million annually post-IPO, based on disclosed R&D timelines. That makes them sensitive to two variables: the durability of risk appetite in small-cap biotech, and the timing of clinical trial readouts relative to their next financing need. If any of these three stumbles in early trading or reports a trial delay within six months, the window will narrow again. Conversely, if all three trade flat-to-up through their first earnings calls, expect another four-to-six IPO filings from venture-backed life sciences companies before July.
Operators with companies in late-stage preclinical or Phase 1 should watch how Seaport and Hemab price relative to Kailera's debut performance in its first ten trading days. If Kailera holds $15.50 or better, the underwriters will have room to price the next wave at similar or tighter valuations without spooking institutional buyers. Family offices considering biotech allocations should focus on cash runway and the distance to the next value-inflection milestone. Companies that can reach Phase 2 data or partnership announcements without needing a follow-on raise within 18 months will separate from those that cannot.
Kailera begins trading Friday on the Nasdaq under ticker KAIL. Seaport and Hemab roadshows are expected to begin within three weeks.